Comparatively, GLP-1 treatment significantly increased VAT metabolism
For those following the development of retatrutide with a view to future use, it is worth noting that NICE guidance on obesity pharmacotherapy including its technology appraisal of semaglutide (Wegovy) for weight management does not specify a preferred time of day for weekly injectable agents
doi:10.3389/fpsyt.2018.00669 Guo EL, Katta R
Correlates with elevated liver fat accumulation even in the absence of obesity
Potential Serious Side Effects and Complications include, but are not limited to: Gastroparesis and chronic gastrointestinal issues (constipation and/or diarrhea) Thyroid C-cell tumor and Medullary thyroid cancer Hypersensitivity reaction, Anaphylaxis and/or Angioedema Acute kidney injury and chronic renal failure exacerbation
[1] General Dosing Considerations: Alpha-Lipoic Acid Injection is administered parenterally (typically by intravenous infusion), and dosing should be individualized by the prescribing physician according to the patients needs and response